Faraday Pharmaceuticals, Inc.   Report issue

For profit Phase 3
Founded: Seattle WA United States (2014)

Organization Overview

First Clinical Trial
2018
NCT03470441
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Faraday Pharmaceuticals, Inc.

Active Ingredients

Drugs in Phase 3 Trials (1)

sodium iodide (3 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Infarction (Phase 2)

Myocardial Infarction (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 3
  • # of Trial APIs: 1